- Joined
- 27 June 2010
- Posts
- 4,147
- Reactions
- 309
The Fiji Kava Group is primarily a biotechnology company whose research and development aspirations are underpinned with an existing business selling kava extracts as a consumer product.
The Company considers that the scale-up and improvement of the underlying kava retail business will be synergistic to the development of additional products and intellectual property from kavalactone research.
The key business objectives of the Company on completion of the IPO are:
https://fijikava.com/
The Company considers that the scale-up and improvement of the underlying kava retail business will be synergistic to the development of additional products and intellectual property from kavalactone research.
The key business objectives of the Company on completion of the IPO are:
- human clinical trials to be developed in consultation with the National Institute of Complementary Medicine (NICM) and the Scientific Advisory Board in order to establish the efficacy and safety of the Company's products, and to develop novel kava extracts and kava combination products. This research is slated to commence in the fourth quarter of 2018;
- the primary production of mkava through a network of outsourced kava farms and via its own Farm located in Fiji; and
- the production and sale of kava supplements and complimentary medicines.
https://fijikava.com/